

SAFETY DATA SHEET



Altren® (Altrenogest Solution 0.22%)

Item # 10-085

1. SUBSTANCE IDENTITY/COMPANY CONTACT INFORMATION

PRODUCT NAME: Altren® (Altrenogest Solution 0.22%)

MOLECULAR FORMULA: Mixture

CHEMICAL FAMILY: Oral Progestin

USE: To suppress estrus in mares.

SUPPLIER:

Aurora Pharmaceutical, LLC

1196 South Highway 3

Northfield, MN 55057

TELEPHONE NUMBERS:

Emergency (Chemtrec 24 hours): (800) 424-9300

Information: (888) 215-1256

2. HAZARDS IDENTIFICATION

Signal word: WARNING

Pictograms



HAZARD STATEMENTS

H303 – May be harmful if swallowed

H313 – May be harmful if contact with skin

H361 – Suspected of causing damage to fertility or the unborn child

H373 – May cause damage to organs from prolonged or repeated exposure

PRECAUTIONARY STATEMENTS

P202 – Do not get in eyes, on skin, or on clothing

P263 – Avoid contact during pregnancy/nursing

P264 – Wash thoroughly after handling

P308 + P313 – If exposed or concerned, get medical advice/attentions

OTHER HAZARDS

CARCINOGENIC STATUS: Progestins as a group, have been classified as IARC Group 2B (Possibly Carcinogenic to Humans). This evaluation applies to the group of compounds as a whole and not necessarily to individual compounds within the group

EFFECTS OF EXPOSURE: May cause effects to: endocrine system, central nervous system, gastrointestinal tract, reproductive system, or fetus. May cause impaired fertility.

3. COMPOSITION/INFORMATION OF INGREDIENTS

Mixture of the substances listed in this section.

INGREDIENT 1

COMMON NAME: Medium Chain Triglycerides

% BY WEIGHT: >70%

CAS NUMBER: na

INGREDIENT 2

COMMON NAME: Benzyl Alcohol

% BY WEIGHT: <10%

CAS NUMBER: 100-51-6

INGREDIENT 3

COMMON NAME: Altrenogest

% Wt/Vol: 0.22 %

CAS NUMBER: 850-52-2

Additional ingredients are present in < 1% of the formulation and are not considered carcinogens.

EXPOSURE LIMIT(S) FOR THE MATERIAL:

Not established.

4. FIRST AID MEASURES

EYES: Remove contact lenses, if present. Rinse immediately with plenty of water, including under the eyelids, for at least 15 minutes. If irritation persists, obtain medical attention.

SKIN: Immediately remove any contaminated clothing and wash with soap and water. If irritation or symptoms occur, seek medical attention.

INHALATION: Move to fresh air. If trouble breathing seek medical attention.

INGESTION: Rinse mouth. Do not induce vomiting. Contact a physician if symptoms persist.

5. FIRE FIGHTING MEASURES

FLASH POINT: 260° C (based on the flash point of Medium Chain Triglycerides).

LOWER EXPLOSION LIMIT (LEL): Not available.

UPPER EXPLOSION LIMIT (UEL): Not available.

EXTINGUISHING MEDIA: Water, foam, carbon dioxide, or dry chemical.

FIRE FIGHTING PROCEDURES: Wear self-contained breathing apparatus and full-body protective equipment.

UNUSUAL FIRE OR EXPLOSION HAZARDS: May form thick soot or smoke.

HAZARDOUS COMBUSTION PRODUCTS: Carbon monoxide, carbon dioxide

| | |
|--|-----------------------------------|
| SAFETY DATA SHEET | Aurora Pharmaceutical, LLC |
| Altren[®] (Altrenogest Solution 0.22%) | Item # 10-085 |

6. ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS: Ensure adequate ventilation. Avoid contact with skin, eyes and clothing.

ENVIRONMENTAL PRECAUTIONS: Do not let product enter drains. Do not flush into surface water. Do not flush to groundwater and soil.

METHODS FOR CLEANING UP: Absorb the liquid with suitable material, then transfer into a suitable container for disposal.

7. HANDLING AND STORAGE

HANDLING: Use with adequate ventilation. Avoid contact with skin, eyes, and clothing. Wash thoroughly after handling. Launder contaminated clothing before reuse.

STORAGE: Store at or below 25°C. Store away from food and beverages. Keep out of reach of children.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

RESPIRATORY PROTECTION: Not required under normal conditions of use.

VENTILATION: Good general ventilation should suffice.

HAND PROTECTION: Protective gloves.

EYE PROTECTION: Safety glasses. Care should be taken to avoid accidental exposure.

OTHER PROTECTIVE EQUIPMENT: For large scale use, Tyvek or other impermeable suits may be necessary to avoid skin contact.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Clear, colorless to slightly yellow solution.

Odor: Not available.

pH: Not available.

Flash Point: 260°C (based on flash point for Medium Chain Triglycerides)

Auto ignition Temperature: NA

Boiling Point/Range: NA

Melting Point/Range: NA

Flammability (solid, gas): NA

Upper/Lower Flammability: NA

Vapor Pressure: NA

Vapor Density: NA

Specific Gravity: 0.93 – 0.96

Water Solubility: No

Reactivity in Water: None

Decomposition Temperature: NA

10. STABILITY AND REACTIVITY

STABILITY: Stable under normal conditions.

PHYSICAL CONDITIONS TO AVOID: Heat - high temperature.

INCOMPATIBILITY WITH OTHER

MATERIALS: Strong oxidizers.

HAZARDOUS DECOMPOSITION PRODUCTS:

Possible Acrolein formation, Carbon dioxide, Carbon monoxide.

HAZARDOUS POLYMERIZATION: Will not occur.

11. TOXICOLOGICAL INFORMATION

ACUTE TOXICITY:

No data is available for the product. The following is for Altrenogest:

LD₅₀ Oral rat >2000mg/kg

CHRONIC TOXICITY:

Not available.

REPRODUCTIVE/DEVELOPMENTAL TOXICITY:

Possible damage to the fetus.

12. ECOLOGICAL INFORMATION

No relevant studies identified.

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHOD: Dispose of by incineration in accordance with applicable local and national regulations.

14. TRANSPORT REGULATIONS

Not regulated by the United States Department of Transportation (DOT), International Maritime Organization (IMO), or International Air Transport Association (IATA).

15. REGULATORY INFORMATION

The following components are listed in the United States TSCA (Toxic Substances Control Act) inventory:

Benzyl Alcohol

| | |
|--|-----------------------------------|
| SAFETY DATA SHEET | Aurora Pharmaceutical, LLC |
| Altren[®] (Altrenogest Solution 0.22%) | Item # 10-085 |

| |
|------------------------------|
| 16. OTHER INFORMATION |
|------------------------------|

Revision Date: 08/20/18

The information and recommendations presented in this SDS are based on sources believed to be accurate. Aurora Pharmaceutical, LLC assumes no liability for the accuracy or completeness of this information. It is the user's responsibility to determine the suitability of the information for their particular purposes.